Check Claims Before You Publish

Visual summary (graphs first)

Top thematic footprint

Ivanov's corpus centers on epithelial junction biology, actin-myosin cytoskeletal regulation, and endocytic trafficking — a coherent, experimentally-driven program linking basic cell mechanisms (actin isoforms, non-muscle myosin II) to epithelial barrier integrity and disease-relevant phenotypes (e.g., atopic dermatitis, intestinal infection susceptibility).

Representative mechanistic papers (selected):

• β/γ-actin MBc 2012
• TJ/AJ endocytosis MBoC 2003
• TJ defects in AD (JACI 2010)

Quantitative profile & interpretation

Key bibliometrics from OpenAlex snapshot: works_count ~202, cited_by_count ~15,366, h-index 50, long publication span with peak citation years (notably 2016 spike in OpenAlex data). These numbers indicate sustained productivity and high-impact contributions in cell biology and epithelial barrier research.

Strengths evident from the record:

1. Consistent mechanistic experiments using complementary tools (RNAi, genetic mouse models, imaging, pharmacology) across cell and animal systems (in vitro ↔ in vivo linkage).
2. Multiple high-citation, field-shaping papers in credible journals (MBoC, AJPathol, JACI), supporting both mechanistic depth and translational relevance.
3. Focus on rigorous cell-biological endpoints (TEER, dextran flux, confocal quantification, knockout/transgenic mouse phenotypes) — not purely correlative work.

Common limitations / blindspots across papers:

• Frequent reliance on transformed epithelial cell lines (Caco-2, HT-29, SK-CO15) and RNAi/peptide approaches — good mechanistic tools but limited direct human physiological inference.
• Some pharmacological tools (e.g., blebbistatin in later NM II work) and isoform-perturbation reagents have specificity issues the authors acknowledge; isoform compensation is an open question in several studies.
• Translational leaps (linking junction changes to clinical disease) are supported by observational clinical data but causal chains often rest on correlative or model-based evidence — an ordinary but important caveat.

Top-works citation comparison (visual)

Critical evaluation — strengths, weaknesses, and reproducibility

Strength: Ivanov's lab shows high methodological competence in cell biology (imaging, junction assays, genetic models) and a consistent program linking cytoskeletal mechanisms to barrier function; multiple papers are independently replicated and highly cited, indicating community uptake and influence.

Weakness: external generalization to human physiology is sometimes limited by model choices (cell lines, mouse models), and where pharmacological tools have limited specificity the mechanistic interpretation requires cautious read-through — the papers generally state these limitations.

Reproducibility: Many methods are standard (siRNA, calcium-switch, TEER, dextran flux, mouse knockouts), improving reproducibility; explicit data/quantification are present in core papers, but some later unpublished datasets and code links are limited (authors usually provide data on request).

Conclusions & practical takeaways

• Ivanov is a credible, methodologically-strong epithelial/cytoskeleton researcher whose work has influenced barrier biology and host-pathogen interface fields (supported by high citation counts of several papers).
• His research program shows coherent thematic progression: molecular/cellular mechanisms → animal models → links to human disease phenotypes.
• Main limitations to watch: reliance on in vitro models for mechanistic claims and some pharmacological specificity issues — future studies using primary human tissues and isoform-specific genetic models would strengthen causal claims.

Representative citations underpinning the evaluation:

• β/γ-actin MBc 2012
• TJ/AJ endocytosis MBoC 2003
• TJ defects in AD (JACI 2010)